The company
Maze Therapeutics, Inc.
MAZE · Nasdaq
MAZE stood above a rising 150-day average in 22 of the last 52 weekly readings, and has been out of that trend for the last 30 weeks. It is 2.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Setting up
- Weeks in an uptrend
- out for 30
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $40.4M
- Officials’ trades on record
- 0
- Institutions holding
- 157 (-3)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 22 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Jason V. ColomaChief Executive Officer | sold | 2,593at $27.02 | 1 Oct 2026filed 2 Oct 2026 |
| Jason V. ColomaChief Executive Officer | sold | 31,908at $27.02 | 1 Oct 2026filed 2 Oct 2026 |
| Harold BernsteinPresident, R&D & CMO | sold | 16,141at $26.93 | 1 Oct 2026filed 2 Oct 2026 |
| Atul DandekarCSBO | sold | 7,500at $27.06 | 29 Sep 2026filed 1 Oct 2026 |
| Harold BernsteinPresident, R&D & CMO | sold | 9,705at $26.22 | 4 Sep 2026filed 8 Sep 2026 |
| Jason V. ColomaChief Executive Officer | sold | 11,282at $26.01 | 3 Sep 2026filed 4 Sep 2026 |
| Jason V. ColomaChief Executive Officer | sold | 129at $25.77 | 3 Sep 2026filed 4 Sep 2026 |
| Phillips CourtneyGC and Corp. Secretary | sold | 1,990at $26.01 | 3 Sep 2026filed 4 Sep 2026 |
| Phillips CourtneyGC and Corp. Secretary | sold | 22at $25.78 | 3 Sep 2026filed 4 Sep 2026 |
| Atul DandekarCSBO | sold | 3,207at $26.01 | 3 Sep 2026filed 4 Sep 2026 |
| Atul DandekarCSBO | sold | 36at $25.81 | 3 Sep 2026filed 4 Sep 2026 |
| Harold BernsteinPresident, R&D & CMO | sold | 5,130at $26.01 | 3 Sep 2026filed 4 Sep 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Frazier Life Sciences Management, L.P.added · filed 14 Aug 2026 | 5,032,915$150.2M | +465,641+10.2% |
| TRV GP IV, LLCunchanged · filed 10 Aug 2026 | 4,473,958$133.5M | 00.0% |
| ARCH Venture Management, LLCunchanged · filed 14 Aug 2026 | 4,120,053$123.0M | 00.0% |
| Deep Track Capital, LPadded · filed 14 Aug 2026 | 3,732,569$111.4M | +255,007+7.3% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 3,502,841$104.5M | +932,416+36.3% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 3,408,045$101.8M | +3,408,045 |
| Logos Global Management LPadded · filed 14 Aug 2026 | 1,935,000$57.7M | +700,000+56.7% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 1,778,222$53.1M | +342,566+23.9% |
| a16z Capital Management, L.L.C.unchanged · filed 14 Aug 2026 | 1,702,225$50.8M | 00.0% |
| Venrock Adviser, LLCunchanged · filed 14 Aug 2026 | 1,602,034$47.8M | 00.0% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.